1wv1: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{Seed}}
[[Image:1wv1.png|left|200px]]
[[Image:1wv1.png|left|200px]]


Line 20: Line 19:


==About this Structure==
==About this Structure==
1WV1 is a 1 chain structure of sequence from [http://en.wikipedia.org/wiki/Oryctolagus_cuniculus Oryctolagus cuniculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1WV1 OCA].  
[[1wv1]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Oryctolagus_cuniculus Oryctolagus cuniculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1WV1 OCA].  


==Reference==
==Reference==
Line 34: Line 33:
[[Category: Wendt, K U.]]
[[Category: Wendt, K U.]]
[[Category: Glycogenolysis]]
[[Category: Glycogenolysis]]
[[Category: Transferase]]
[[Category: Type 2 diabetes]]
[[Category: Type 2 diabetes]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Feb 17 17:58:32 2009''

Revision as of 23:21, 14 March 2011

File:1wv1.png

Template:STRUCTURE 1wv1

Crystallographic studies on acyl ureas, a new class of inhibitors of glycogenphosphorylase. Broad specificity of the allosteric siteCrystallographic studies on acyl ureas, a new class of inhibitors of glycogenphosphorylase. Broad specificity of the allosteric site

Template:ABSTRACT PUBMED 15987904

About this StructureAbout this Structure

1wv1 is a 1 chain structure with sequence from Oryctolagus cuniculus. Full crystallographic information is available from OCA.

ReferenceReference

[xtra 1][xtra 2][xtra 3][xtra 4][xtra 5]

  1. Oikonomakos NG, Kosmopoulou MN, Chrysina ED, Leonidas DD, Kostas ID, Wendt KU, Klabunde T, Defossa E. Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs. Protein Sci. 2005 Jul;14(7):1760-71. PMID:15987904 doi:14/7/1760
  2. Klabunde T, Wendt KU, Kadereit D, Brachvogel V, Burger HJ, Herling AW, Oikonomakos NG, Kosmopoulou MN, Schmoll D, Sarubbi E, von Roedern E, Schonafinger K, Defossa E. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. J Med Chem. 2005 Oct 6;48(20):6178-93. PMID:16190745 doi:10.1021/jm049034y
  3. Zographos SE, Oikonomakos NG, Tsitsanou KE, Leonidas DD, Chrysina ED, Skamnaki VT, Bischoff H, Goldmann S, Watson KA, Johnson LN. The structure of glycogen phosphorylase b with an alkyldihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. Structure. 1997 Nov 15;5(11):1413-25. PMID:9384557
  4. Oikonomakos NG, Tsitsanou KE, Zographos SE, Skamnaki VT, Goldmann S, Bischoff H. Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarbo xylate. Protein Sci. 1999 Oct;8(10):1930-45. PMID:10548038
  5. Kristiansen M, Andersen B, Iversen LF, Westergaard N. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site. J Med Chem. 2004 Jul 1;47(14):3537-45. PMID:15214781 doi:10.1021/jm031121n

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA